| Symbol | ALKS |
|---|---|
| Name | ALKERMES PLC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | CONNAUGHT HOUSE, DUBLIN 4, L2 00000 |
| Telephone | 00-353-1-772-8000 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | None |
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Read moreFindings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
Read moreDirector Lurker Nancy 🟡 adjusted position in 901 shares (1 derivative) of Alkermes plc. (ALKS) at $33.36 Transaction Date: Apr 11, 2026 | Filing ID: 000070
Read moreNew Form ARS - Alkermes plc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001193125-26-144016 <b>Size:</b> 3 MB
Read moreNew Form DEFA14A - Alkermes plc. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0001193125-26-144001 <b>Size:</b> 2 MB
Read moreHopkinson Craig C. 🟡 adjusted position in 9.0K shares (1 derivative) of Alkermes plc. (ALKS) at $35.51 Transaction Date: Apr 01, 2026 | Filing ID: 000065
Read more📋 Hopkinson Craig C. (Officer) plans to sell 9K shares of Alkermes plc. (at $35.51 each, total $320K) Filed: Apr 01, 2026 | ID: 000196
Read moreAlkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Read moreNew Form SCHEDULE 13G/A - Alkermes plc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000438 <b>Size:</b> 7 KB
Read more